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RBACKGROUND & AIMS: Patients with acute liver failure (ALF)
have defects in innate immune responses to microbes (immune
paresis) and are susceptible to sepsis. Cytotoxic T-lymphocyte
associated protein 4 (CTLA4), which interactswith themembrane
receptor B7 (also called CD80 andCD86), is a negative regulator of
T-cell activation. We collected T cells from patients with ALF and
investigated whether inhibitory signals down-regulate adaptive
immune responses in patientswith ALF.METHODS:Wecollected
peripheral blood mononuclear cells from patients with ALF and
controls from September 2013 through September 2015 (45 pa-
tients with ALF, 20 patients with acute-on-chronic liver failure, 15
patientswith cirrhosis with no evidence of acute decompensation,
20 patients with septic shock but no cirrhosis or liver disease, and
20healthy individuals). Circulating CD4þ T cellswere isolated and
analyzed by ﬂow cytometry. CD4þ T cells were incubated with
antigen, or agonist to CD3 and dendritic cells, with or without
antibody against CTLA4; T-cell proliferation and protein expres-
sion were quantiﬁed. Wemeasured levels of soluble B7molecules
in supernatants of isolated primary hepatocytes, hepatic sinusoi-
dal endothelial cells, and biliary epithelial cells from healthy or
diseased liver tissues. We also measured levels of soluble B7
serum samples from patients and controls, and mice with
acetaminophen-induced liver injury using enzyme-linked immu-
nosorbent assays. RESULTS: Peripheral blood samples from
patients with ALF had a higher proportion of CD4þ CTLA4þ
T cells than controls; patients with infections had the highest
proportions. CD4þ T cells from patients with ALF had a reduced
proliferative response to antigen or CD3 stimulation compared to
cells from controls; incubation of CD4þ T cells from patients with
ALF with an antibody against CTLA4 increased their proliferative
response to antigen and to CD3 stimulation, to the same levels as
cells from controls. CD4þ T cells from controls up-regulated
expression of CTLA4 after 2448 hours culture with sera from
patients with ALF; these sera were found to have increased
concentrations of soluble B7 compared to sera from controls.
Necrotic human primary hepatocytes exposed to acetaminophen,
but not hepatic sinusoidal endothelial cells and biliary epithelial
cells from patients with ALF, secreted high levels of soluble B7.
Sera from mice with acetaminophen-induced liver injurycontained high levels of soluble B7 compared to sera from mice
without liver injury. Plasma exchange reduced circulating levels
of soluble B7 in patients with ALF and expression of CTLA4 on
T cells. CONCLUSIONS: Peripheral CD4þ T cells from patients
with ALF have increased expression of CTLA4 compared to in-
dividuals without ALF; these cells have a reduced response to
antigen and CD3 stimulation. We found sera of patients with ALF
and from mice with liver injury to have high concentrations of
soluble B7, which up-regulates CTLA4 expression by T cells and
reduces their response to antigen. Plasma exchange reduces levels
of B7 in sera from patients with ALF and might be used to restore
antimicrobial responses to patients.
Keywords: Immune Regulation; Liver Disease; Treatment;
Infection Susceptibility.
cute liver failure (ALF) occurs after a severe hepaticAinsult resulting in a rapidly progressive clinical
syndrome characterized by jaundice, encephalopathy,
coagulopathy, and multiple organ dysfunction.1,2 Although
the initiating event in ALF is acute hepatocellular death,
mortality is attributable to a profound activation of systemic
inﬂammatory response syndrome and multiple organ
EDITOR’S NOTES
BACKGROUND AND CONTEXT
Systemic innate immune defects are well-characterized
as contributors to immuneparesis and susceptibility to
infections in patients with acute liver failure (ALF).
However, dysfunctions in adaptive immune responses
were unexplored.
NEW FINDINGS
Following acute liver injury, peripheral CD4þ T cells in ALF
patients display an increased expression of cytotoxic T
lymphocyte-associated molecule-4 (CTLA4) with an
inhibitory functional aspect that dampens protective
immunity.
LIMITATIONS
Experimental models for assessing the role of CTLA4 in
ALF.
IMPACT
This work has identiﬁed a novel therapeutic target to
reverse immune dysfunctions in patients with ALF.
264 Khamri et al Gastroenterology Vol. 153, No. 1
BASIC
AND
TRANSLATIONAL
LIVERdysfunction.1–3 Recent studies identify defects in innate
immune responses to microbial cues, termed immune
paresis, which cause an increased susceptibility to second-
ary infections, a leading cause of mortality in ALF.4–7
After acute tissue injury, intracellular components,
deﬁned as damage-associated molecular pattern molecules
or alarmins, are released by necrotic and apoptotic cells and
act as “danger” signal molecules that trigger organ-speciﬁc
and systemic inﬂammatory response syndrome.8,9 Studies
identify profound elevations in these danger signals in
patients with acute hepatic inﬂammatory disorders, which
have recently been shown to modulate the function of
myeloid and possibly lymphoid cells.10–12
Substantial evidence exists in nonhepatic inﬂammatory
disorders (eg, severe trauma, pancreatitis, septic shock) of
suppression in T-cellmediated antimicrobial responses
that account for the immune paresis and infectious com-
plications encountered in these patients.9,13 The acquired
immune dysfunction reported in sepsis includes increased
regulatory T cells with elevated levels of inhibitory receptor
including PD-1 and CTLA4,13,14 which correlate with
reduced interferon (IFN) gamma production and low T-cell
proliferative capacity.15 In murine models of sepsis, CTLA4
was also reported to be elevated on CD4þ and CD8þ T
cells.16 Accordingly, blocking PD-1 and CTLA4-mediated
negative regulatory pathways demonstrated improved sur-
vival in animal models of bacterial and fungal sepsis,
increased pathogen clearance, and reversed T-cell dysfunc-
tion in patients with sepsis.16,17 However, it remains to be
determined whether defects in peripheral adaptive immune
responses play a role in the immune paresis reported in
ALF.
CTLA4 (CD152) is a well-characterized negative regu-
lator expressed on T cells that binds to the same ligands
(CD80 and CD86) as CD28, but with a higher afﬁnity.18 Upon
T-cell activation, CTLA4 cycles to the cell surface and exertsits inhibitory effect, which results in attenuated T-cell re-
sponses and inhibition of interleukin (IL)-2 secretion, a
critical cytokine for T-cell expansion.19,20 In humans, CTLA4
has been implicated in numerous autoimmune diseases,
such as rheumatoid arthritis and systemic lupus erythe-
matosus.21,22 In severe sepsis, CTLA4 is up-regulated,
resulting in impairment in T-cell activation and antimicro-
bial responses.17,23 CTLA4 was the ﬁrst immune checkpoint
receptor to be clinically targeted and several studies have
demonstrated that antibody blockade of CTLA4 could result
in anti-tumor immunity.24,25
In this study, we sought to assess the immunologic
competence of CD4þ T cells in patients with ALF by exam-
ining their phenotype and function. Here, we identify
adaptive immune dysfunction in CD4þ T cells due to a sus-
tained expression of the negative regulator of T-cell activa-
tion, CTLA4, via mechanisms that involve soluble B7 (sB7)
ligands. The impairment of peripheral CD4þ T cells adaptive
responses in ALF can contribute to the susceptibility to
infections seen in these patients.Methods
Patient Characteristics
All patients were consecutively recruited from September
2013 to September 2015. Subjects were recruited to the study
within 24 hours of admission to the liver intensive therapy unit
or liver wards. Patients were categorized into the following
groups: ALF (n ¼ 45: 35 acetaminophen-induced ALF [AALF]
and 10 non-AALF, patients with acute-on-chronic liver failure
(ACLF; n ¼ 20), chronic liver disease (CLD) patients with
cirrhosis with no evidence of acute decompensation (n ¼ 15),
patients with septic shock with no underlying cirrhosis/liver
disease (sepsis group; n ¼ 20), healthy controls (HC; n ¼ 20). A
subset of ALF patients underwent sequential sampling on day 3
(n ¼ 7), day 7 (n ¼ 8), and day 14 (n ¼ 5) after admission. In
addition, a subset of ACLF patients underwent sequential
sampling on day 3 (n ¼ 5), day 7 (n ¼ 4), and day 14 (n ¼ 5).
When plasma exchange (PE) was instituted in ALF patients
recruited, additional sampling was performed immediately
before PE (pre-PE, n ¼ 7) and within 8 hours after completion
of PE (post-PE; n ¼ 7). All patients who fulﬁlled criteria for ALF
were transferred to liver intensive therapy unit based on
published referral guidelines for both AALF and non-AALF.26
Patients with ACLF fulﬁlled the established diagnostic criteria
developed by the European Association for the Study of the
Liver-Chronic Liver Failure consortium.27 This study was
approved by the King’s College Hospital ethics committee (12/
LO/0167). Informed consent was obtained by the next of kin if
patients were not able unable to provide consent.
Phenotyping Using Flow Cytometry
Peripheral blood mononuclear cells isolated through
density-gradient centrifugation were surface stained for CD3,
CD4, CD8, CD45RA, CD45RO, CCR-7, CTLA4, PD-1, CD25,
CD62L, CD28, CD40L, and CD127. Twelve-color ﬂow cytometric
analyses were performed using an LSR Fortessa ﬂow cytometer
and data were acquired using BD FACSDiva software (Becton
Dickinson Ltd, Oxford, UK).
Figure 1. Phenotypic characterization of T-cell subsets in peripheral blood mononuclear cells of ALF patients. Gating strategy to
deﬁne lymphocyte subsets is described in the Supplementary Materials (Supplementary Figure 1). (A) Immunophenotyping of
circulating lymphocytes using ﬂow cytometry. Data show the percentages of circulating CD3þ CD4þ, and CD8þ T cells in ALF
compared with HC and pathologic control groups. (B) Distribution of naïve CD45RORAþ and memory CD45ROþRA
subpopulations within the expanded CD4þ T-cell population in ALF compared with healthy and pathologic control groups. Left:
Data show ratios of percentage of expression. CD4þ T cells were subgrouped into effector memory T cell
(CD3þCD4þCD8CCR7þCD45RO) (middle panel) and Tcm (CD3
þCD4þCD8CCR7þCD45ROþ) populations (right panel). Per-
centages of expression are shown (HC, n¼ 20; ALF, n¼ 45; ACLF, n¼ 20; CLD; n¼ 15, patientswith septic shockwith no underlying
cirrhosis/liver disease [sepsis], n ¼ 20).
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Proliferation
Speciﬁc CD4þ T-cell antigen-recall responses to a pool of
HLA class II-restricted T-cell epitopes at 10 mg/mL (CTL Europe
GmbH, Bonn, Germany) were examined in vitro for T-cell pro-
liferation using either carboxyﬂuorescein succinimidyl ester or
cell proliferation dye eFluor 670 (eBioscience, Hatﬁeld, UK)
labeling, in the presence or absence of anti-CTLA4 blocking
antibody (10 mg/mL; eBioscience). All blocking antibodies used
in this study were referenced neutralizing antibodies from the
manufacturers. CD4þ T-cell proliferation was tested by labeling
peripheral blood mononuclear cells with carboxyﬂuorescein
succinimidyl ester before being placed in culture for 6 days.
Peripheral blood mononuclear cells were cultured in RPMI
1640 (Thermo Fisher Scientiﬁc, Hemel Hempstead, UK) sup-
plemented with 10% human AB serum (PAA Laboratories Ltd,
West Yorkshire, UK). After stimulation for 6 days at 37C in 5%
CO2, cells were harvested and stained for surface markers (CD3,
CD4, and CD8). Data were collected using LSR Fortessa (Becton
Dickinson) and analyzed using FlowLogic (Inivai Technologies
Pty Ltd, Victoria, Australia).
Dendritic Cell CD4þ T-Cell Co-Culture
Allogeneic dendritic cells (DCs) were generated as described
previously.28 They were then co-cultured with CD4þ T cells from
ALF patients in the presence of anti-CD3 (a-CD3) antibody
(0.5 mg/mL) (eBioscience, Hatﬁeld, UK) at optimal ratio of 1:40(DC to CD4þ T cells) ratio, which was selected after a dos-
eresponse testing (ranging from 1:1 to 1:80 DC to CD4þ T cells
ratio). Cellswere co-cultured for 5 days in the presence or absence
of anti-CTLA4 (a-CTLA4) (10 mg/mL). Cell division of CD4þ T cell
was measured by the dilution of carboxyﬂuorescein succinimidyl
ester dye using ﬂow cytometry.Effect of Circulating Soluble B7 on Cytotoxic
T-LymphocyteAssociated Protein 4 Expression
CD4þ T cells isolated fromHCwere cultured in freshmedium
for 24 and 48 hours at 5  105 cells per well in the presence of
10% ALF (n ¼ 14) or HC (n ¼ 12) sera and screened for CTLA4
surface expression using ﬂow cytometry. Supernatant were
collected for subsequent detection of cytokines. Sera samples
from both HC and ALF patients were pre-incubated with anti-
human CD80 or CD86 neutralizing antibodies (a-CD80 or a-
CD86) (R&D Systems, Abingdon, UK) for 45 minutes at room
temperature before addition to CD4þ T cells isolated from
healthy donors. Cell culture supernatants were collected for
assessing cytokine secretion. Cells were harvested for pheno-
typing. Unless otherwise stated, sB7 molecules refer to sCD80
and sCD86.Primary Human Hepatocytes and Kupffer Cells
Cryopreserved hepatocytes (Invivogen, Paisley, UK) were
cultured for 24 hours in the presence or absence of 20 mM
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LIVERacetaminophen (APAP) (Sigma, Dorset, UK). Cells were
stained using apoptotic/necrotic cell kit (PromoCell GmbH,
Heidelberg, Germany). Apoptosis and necrosis were detected
using Annexin V, ethidium homodimer III, respectively, ac-
cording to manufacturer’s instructions. Kupffer cells (Inviv-
ogen) were stimulated overnight in the presence of
lipopolysaccharide (100 ng/mL). Supernatants from hepato-
cyte and Kupffer cell cultures were collected for assessment of
sB7 molecules.Figure 2. Percentages of CTLA4-expressing CD4þ T cells are ele
to determine CTLA4-expressing CD4þ T cells in HC (left), ALF
percentages of circulating CD4þ T cells expressing CTLA4 are
(C) CTLA4 levels were determined in sequential samples at da
compared to HC levels, represented by the dashed line. (D) Lef
naïve, and memory subsets using CD25 and CD127 markers. R
subsets, mainly naïve and memory subsets on day 1 of subm
patients who developed infections (n ¼ 11) and the ones w
CTLA4þCD4þ among memory and naïve T-cell subsets assesse
and 14 (n ¼ 5) after admission.Isolation and Culture of Hepatic Sinusoidal
Endothelial Cells and Biliary Epithelial Cells
Hepatic sinusoidal endothelial cells (HSECs) and biliary
epithelial cells were isolated according to methods described
previously,29 approved by the University of Birmingham ethics
committee (06/Q2702/61). HSECs were cultured in the pres-
ence of sera from ALF (n ¼ 6) and HC (n ¼ 6) at 25%. Su-
pernatants were then collected and assessed for sB7 molecules.
Sera preconditioned HSECs were cultured for an additional 24vated in ALF patients. (A) Representative ﬂow cytometry plots
(middle), and pathologic controls (right). (B) Data show that
signiﬁcantly elevated in ALF compared to HCs (P < .0001).
ys 3 (n ¼ 7), 7 (n ¼ 8), and 14 (n ¼ 5) after admission and
t: Representative plot to deﬁne CD3þCD4þ regulatory T cells,
ight: Distribution of CTLA4 expression in different CD4þ T cell
ission (n ¼ 15). (E) CTLA4 expression was assessed in ALF
ho did not develop infections (n ¼ 23). (F) Distribution of
d in longitudinal samples on days 1 (n ¼ 6), 3 (n ¼ 7), 7 (n ¼ 8),
Table 1.Clinical and Physiological Characteristics of
Culture-Positive Infected and Noninfected
Acetaminophen Acute Liver Failure Patients
Parameter Infected AALF Noninfected AALF
Patients, n 11 24
Age, y 31.00 (27.0049.00) 36.00 (27.0048.00)
WBC, 109/L 6.700 (5.9108.130) 8.710 (5.92511.61)
Monocytes,
109/L
0.2000 (0.13000.2600) 0.3200 (0.12500.6050)
Lymphocytes,
109/L
0.5100 (0.30000.7400) 0.7400 (0.32001.105)
SIRS score 3.000 (2.0004.000) 3.000 (2.0004.000)
MELD score 39.00 (37.0043.00) 39.00 (31.0041.00)
Bilirubin, mmol/L 70.00 (44.00140.0) 90.00 (69.00162.0)
INR 4.040 (2.8706.250) 4.480 (2.4806.340)
Creatinine, mmol/L 259.0 (90.00360.0) 93.00 (63.00239.5)
Urea, mmol/L 11.30 (5.70014.00) 7.000 (4.9008.700)
AST, IU/mL 4703a (25218861) 1665 (951.53756)
Ammonia, mmol/L 87.50 (54.75138.5) 99.00 (67.50150.3)
Encephalopathy
score
3.000b (3.0004.000) 2.000 (1.0003.000)
b
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necrosis factora and 10 ng/mL IFN gamma (PeproTech,
London, UK). Supernatants were collected for assessment of
sB7 molecules.
Co-Culture of Monocytes With
Apoptotic Neutrophils
Neutrophils were isolated by density gradient centrifu-
gation as described previously.30 Neutrophils were resus-
pended (106 cells/mL) in fresh complete medium and
incubated for 20 hours (37C in 5% CO2) in 24-well plates
(Corning Inc, Tewksbury, MA). Annexin-V kit (BD Bio-
sciences) was used to determine the percentage of apoptotic
neutrophils, which was >65%, as described previously.30
Next, CD14þ monocytes were resuspended (0.5  106
cells/mL) and co-incubated in 1:2 ratio for 4 hours with
apoptotic neutrophils. Supernatants were collected in order
to measure sB7 levels by enzyme-linked immunosorbent
assay.
Enzyme-Linked Immunosorbent Assay and
Meso Scale Discovery Multiplex Cytokine
Detection System
Soluble B7 were assessed in cell culture supernatants,
human sera, and APAP-induced liver injury model murine
models using enzyme-linked immunosorbent assays. Cytokines
were also assessed in cell culture supernatant using
enzyme-linked immunosorbent assay and Multiplex Cytokine
Detection System (Meso Scale Discovery, Gaithersburg, MD).
Statistical Analysis
Parametric statistical analysis was performed using the
Student t test. Nonparametric analysis was carried out using
the MannWhitney U test, Wilcoxon matched-pairs signed
rank and KruskalWallis tests, and data are expressed as
median (interquartile range [IQR]). For correlations of
CD4þCTLA4þ T-cell frequency and clinical characteristics as
well as correlations of sB7 ligands and disease severity
indices, Spearman rank correlation coefﬁcients were used.
Statistical signiﬁcance was assumed for P < .05. All analyses
were performed using GraphPad Prism software (GraphPad
Inc, La Jolla, CA).
Other details and additional experimental procedures are
provided in the Supplementary Material.CTLA4, % 3.005 (0.85756.418) 1.200 (0.67503.015)
Outcomes,c n
OLT 2 8
Survivors 6 16
Nonsurvivors 3 0
NOTE. Values are median (IQR) unless otherwise noted.
ALD, acute liver disease; AST, aspartate aminotransferase;
INR, international normalized ratio; MELD, Model for
End-Stage Liver Disease; OLT, orthotopic liver
transplantation; NA, not applicable; ND, not determined;
SIRS, systemic inﬂammatory response syndrome criteria
score.
aP ¼ .01.
bP < .002, compared to noninfected.
cOutcomes at 28 days post admission.Results
Patient Characteristics
There was no signiﬁcant difference in median ages of
ALF patients when compared to HC, while pathologic
patients groups were signiﬁcantly older (Supplementary
Table 1). ALF patients have signiﬁcantly higher biochem-
ical and physiologic indices of acute liver injury (eg, Model
for End-Stage Liver Disease, international normalized ratio,
creatinine, and bilirubin) compared to CLD, ACLF, and sepsis
patients (Supplementary Table 1). The number of circu-
lating lymphocytes was reduced signiﬁcantly in ALF
patients when compared to CLD and ALCF patients(Supplementary Table 1), although no differences were seen
when compared with sepsis patients. In addition, lympho-
cyte counts in AALF correlated negatively with indices of
severity of liver injury (international normalized ratio:
r ¼ 0.285, P ¼ .04; aspartate aminotransferase:
r ¼ 0.465, P ¼ .001; systemic inﬂammatory response
syndrome scores: r ¼ 0.391, P ¼ .009; and Model for End-
Stage Liver Disease scores: r ¼ 0.557, P ¼ .0001). The
demographic and key clinical characteristics of patients are
summarized in Supplementary Table 1. Clinical data for ALF
patients who underwent PE are summarized in
Supplementary Table 2.Increased Frequency of Circulating CD4þ T Cells
in Acute Liver Failure Patients With a
Predominantly Naïve Phenotype
In ALF patients, there is an increase in the proportion
of circulating CD4þ T cells (median 64.01%; IQR, 56.51%
71.61%) when compared to healthy (47.17%; 45.17%
58.12%) (P ¼ .003) and pathologic controls (CLD 65.64%;
IQR, 51.9%74.07%), ACLF (57.30%; IQR, 46.54%69.56%),
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(Figure1A). No signiﬁcant changeswere seen in theproportion
of circulating CD8þ T cells in ALF when compared to HC
and pathologic control groups (Figure 1A). The distribution
of naïve and memory subsets is markedly different,
highlighted by a diminished proportion of memory
population (CD4þCD45ROþCD45RA) and an increasedproportion of naïve cells (CD4þCD45ROCD45RAþ) in
ALF compared with HC subjects (ratio memory to naïve:
0.4513%; IQR, 0.3328%0.7557% vs 0.7825%; IQR,
0.5961%1.338; P ¼ .001) (Figure 1B). The reduction in the
memory population was predominantly in the effector mem-
ory T-cell subset (CD4þCCR7CD45ROþ) (P ¼ .002)
(Figure 1B).
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Liver Failure Are Characterized by an
Immunosuppressive Cytotoxic
T-LymphocyteAssociated Protein
4Positive Phenotype
We assessed the surface expression of activation and
inhibitory markers of T-cell function. Compared to ACLF,
CLD patients, and healthy controls, CTLA4 surface expres-
sion was markedly elevated in CD4þ T cells from ALF
patients on admission to the liver intensive care unit
(P < .0001) (Figure 2A and B). The increase in CTLA4
expression is detected in both AALF and non-AALF patients
(1.390%; IQR, 0.6800%6.418% in AALF and 1.985%; IQR,
1.020%4.470% in non-AALF compared to 0.1750%; IQR,
0.0325%0.6225% in healthy controls). In line with pre-
vious reports, septic shock patients also showed high levels
of CTLA4 expression when compared to healthy individuals
(Figure 2B). However, levels in septic shock patients were
signiﬁcantly lower that detected in ALF patients (P ¼ .001).
Analyses of CTLA4 expression in sequentially collected ALF
samples showed that the proportion of CTLA4 expressing
CD4þ T cells remained signiﬁcantly higher than healthy
controls throughout the course of admission (Figure 2C). At
day 3 post-admission, CTLA4 levels of expression peaked,
2.5-fold higher than day-1 levels (P ¼ .02) (Figure 2C).
Detailed immunophenotypic analyses of CD4þ T cells
revealed no signiﬁcant differences in the frequencies of cells
expressing CD25, PD1, CD40L CD28, and CD62L among
CD4þ T cells in the studied groups (Supplementary
Figure 2).
Distribution of Cytotoxic
T-LymphocyteAssociated Protein
4 Expression in Different CD4þ
T-Cell Subsets
We extended the observations reported here and investi-
gated the distribution of CTLA4 expression on the CD4þ naïve
and memory T-cell subsets distinguished based on expression
of CD25, CD127, and CD45RA markers. The distribution of
CTLA4 expression differed among ALF CD4þ T-cell subsets
compared to HC. As illustrated in Figure 2D, CTLA4 expression
was elevated in all CD4þ T cells, most marked in the memory
(CD25CD127CD45RA) when compared to the naïve
(CD25lowCD127þCD45RAþ) subset. In line with previously
published studies in systemic inﬂammatory pathologies,31=
Figure 3. Attenuated ALF recall responses to HLA class IIrest
from HCs (n ¼ 5) and ALF (n ¼ 5) were labeled with carboxyﬂuo
class II-restricted T-cell peptide pool at 10 mg/mL and examin
antibody (10 mg/mL). Recall responses induced in the CD3þCD
percentages of proliferating cells. Representative ﬂow cytometr
marker gate) in HCs (left) and ALF (right) and assessed in the abs
antibody. (B) The resulting proliferation (B, left) and IL2 producti
linked immunosorbent assays, respectively. (C) Proliferation in
sepsis (n ¼ 6) after neutralization of CTLA4. (D) CTLA4 blockade
the memory subset (n ¼ 5). (E) Representative ﬂow cytometry
patients labeled with CPD eFluor 670 and co-cultured with mono
the presence of a-CD3 antibody (left histogram). Data show the
absence of a-CTLA4 in ALF (n ¼ 8), CLD (n ¼ 4), ACLF (n ¼ 4)levels were also high in the T-regulatory subset
(CD25þCD127) (Supplementary Figure 4).
CD4þ Cytotoxic T-LymphocyteAssociated
Protein 4Positive T Cells Correlate With Disease
Severity and Infectious Complications in Acute
Liver Failure
CTLA4 expression by CD4þ T cells was higher in patients
who developed culture positive infections compared to
noninfected patients (P¼ .04) (Figure 2E). When assessed for
correlation with their corresponding clinical parameters, pa-
tients sampled on day 1 of admission who later developed
culture-positive infection had elevated frequency of
CTLA4þCD4þ T cell, which correlated positively with Model
for End-Stage Liver Disease score (r ¼ 0.675, P ¼ .01)
(Figure 2E) and ammonia (r ¼ 0.771, P ¼ .07) (Table 1). An-
alyses of the distribution of CTLA4 expression among naïve
and memory subsets in patients after admission revealed that
percentage ofmemory cells expressing CTLA4peaked onday3
after admission (Figure 2E), particularly within the infected
cohort (1.330%; IQR, 0.190%2.470% on day 1 compared to
9.320%; IQR, 0.800%17.84% on day 3) (Supplementary
Figure 5). No differences were noted in the distribution of
CTLA4 when infected ACLF groups were compared to nonin-
fected ACLF (Supplementary Figure 3A and B).
Defects in CD4þ-Mediated T-Cell Responses
Are Restored Through Blocking Cytotoxic
T-LymphocyteAssociated Protein 4
To investigate whether phenotypic changes reﬂect a
change in the functional capacity in CD4þ T cells in ALF, we
assessed the proliferative capacity of CD4þ T cells using
both antigen-dependent and independent systems. Firstly,
in response to major histocompatibility complex class
IIrestricted recall antigens, we reveal that T-cell prolifer-
ation and IL2 secretion were signiﬁcantly reduced in ALF
(P ¼ .008 and P ¼ .02, respectively) when compared to HC
(Figure 3A and B). T-cell proliferation was reversed after
blockade of the CTLA4 pathway (P ¼ .007) (Figure 3C).
Signiﬁcant increases in T-cell proliferation after CTLA4
pathway blockade in ACLF or CLD patient groups was not
detected (Figure 3C). IL2 production was induced after
CTLA4 blockade in ALF (12.50 pg/mL; IQR, 9.81040.25
pg/mL) (P ¼ .01). IFN gamma levels were also restored, but
did not reach statistical signiﬁcance (Supplementaryricted T cell epitopes. (A) peripheral blood mononuclear cells
rescein succinimidyl ester and stimulated for 6 days with HLA
ed in vitro in the presence or absence of a-CTLA4 blocking
8CD4þ T-cell population were assessed and expressed as
y histograms of the proliferation responses (shown within the
ence (top panels) or the presence (bottom panels) of a-CTLA4
on (B, right) were determined by ﬂow cytometry and enzyme-
CD4þ T cells in ALF (n ¼ 8), CLD (n ¼ 4), ACLF (n ¼ 4), and
using a-CTLA4 antibody restored proliferation particularly in
histograms of proliferation of isolated CD4þT cells from ALF
cyte-derived healthy donor DCs (1:40 DC/CD4þ T-cell ratio) in
resulting proliferation at day 5 (right panel) in the presence or
, and sepsis (n ¼ 6).
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capabilities was most pronounced in memory
CD4þCD45ROþ subset (Figure 3D). Then, we determined
whether CD4þ T cells from ALF patients responded to T-cell
receptormediated activation with a-CD3 antibody in the
presence of allogeneic healthy donor-monocytederived
DCs. CD4þ T cells isolated from HCs underwent more cell
divisions in co-culture with allogeneic DCs after a-CD3
antibody stimulation than the high expressing CTLA4 CD4þ
T cells derived from ALF patients (Figure 3E). To conﬁrm
the suppressive effect of CTLA4 in CD4þ T cells from ALF
patients, co-cultures were carried out in the presence of
anti-CTLA4 antibody. Blocking CTLA4 activity restored
CD4þ T-cell proliferation (P ¼ .03) and IL2 production
(114.8 pg/mL; IQR, 61.51172.4 pg/mL compared to 244.1
pg/mL; IQR, 165.9294.6 pg/mL after blocking CTLA4)
(P ¼ .04). Analyses of CD4þ T-cell function after CTLA4
blockade revealed no signiﬁcant differences in the ACLF and
CLD patient groups (Figure 3E).
Soluble Circulating Mediators in Acute
Liver Failure Regulate Cytotoxic
T-LymphocyteAssociated Protein
4 Expression
In view of the importance of the inﬂammatory micro-
environment in modulating immune cell function in
ALF,4,6,7,32 we investigated the effects of sera, derived from
ALF patients, on CTLA4 expression in CD4þ T cells from HC.
Exposure to sera from ALF patients resulted in up-
regulation of CTLA4 expression on CD4þ T cells after 24
and 48 hours in culture (P ¼ .01) (Figure 4A). Similar to the
effect of sera from ALF patients, we report an elevation in
CTLA4 expression after exposure to sera from sepsis pa-
tients. However, these levels were still signiﬁcantly lower
than what we detect after exposure to sera derived from
ALF patients (Figure 4B). No effect on CTLA4 up-regulation
was detected in cultures of CD4þ T cells in sera derived
from ACLF and CLD patients (Figure 4B).
In order to provide a mechanistic explanation for the
activation of the CTLA4 pathway in ALF, we sought to
investigate the role of circulating sB7 molecules (sCD80 and
sCD86). Here, we detected a marked elevation in circulating
concentrations of sCD80 and sCD86 in ALF compared with
sera from ACLF, CLD, and HCs (Figure 4C, E). Similar to the
CTLA4 levels, sB7 concentrations peaked at day 3 of=
Figure 4. Effect of circulating soluble mediators on CTLA4 expres
supplemented with HC (n ¼ 12) or ALF sera (n ¼ 14) were analyz
CTL4 levels in puriﬁed CD4þ T cells conditioned in media supplem
10) sera in comparison to levels induced by culture in the prese
costimulatory molecules sCD80 and CD86 in sera samples from A
assay (ELISA). (D) sCD80 and sCD86 in sequential samples onday
Circulating levels of sCD86 and sCD80 in sera from ALF (n ¼ 2
determined by ELISA. (F) Healthy and ALF sera were preincuba
respectively. Results are representative of 8 independent expe
demonstrating proliferation percentages of carboxyﬂuorescein s
sera in the absence (left histogram) or presence (right histogram
Proliferation (middle panel) and IL2 secretion (right panel) are froadmission (P ¼ .03) and remained persistently elevated
until day 14 (Figure 4D).
We hypothesized that high levels of circulating sB7
detected in ALF are responsible for the activation of the
CTLA4 pathway in circulating CD4þ T cells. To test this
hypothesis, we assessed the effect of neutralizing sCD80 and
CD86 in ALF sera before exposure to CD4þ T cells from HCs.
As shown in Figure 4F, elevations in CTLA4-expressing
CD4þ T cells were signiﬁcantly reduced, while prolifera-
tion and IL2 secretion were augmented (P ¼ .01 and P ¼
.002, respectively) after neutralization of sCD80 and sCD86
in sera derived from ALF patients when compared to HC
(Figure 4F). Similarly, we report an increase in levels of IFN
gamma, but this did not reach statistical signiﬁcance
(Supplementary Figure 6B).Soluble B7s Are Secreted by Injured Hepatocytes
in Acute Liver Failure
In order to investigate the source of the increased circu-
lating levels of sB7 molecules in the circulation, we assessed
the ability of hepatic parenchymal (hepatocytes and biliary
epithelial cells) and nonparenchymal cells (Kupffer cells,
monocytes) to release sB7 after in vitro and in an in vivo
model of APAP-induced acute liver injury. Although immune
cells, HSECs, and biliary epithelial cells in ALF did not release
increased concentrations of sB7, APAP-treated necrotic pri-
mary human hepatocytes (Figure 5A) released high levels of
sB7 (Figure 5B). No detectable levels of sB7 ligandswere seen
in all tested activated and nonactivated immune and nonim-
mune cell types. Epithelial cell death was further validated by
assessing levels of cell death markers (caspase-cleaved [CK-
18 {M30}] and total cytokeratin [CK-18 {M65}])
(Figure 5B). In addition to elevated levels of sB7, primary
human hepatocytes secreted elevated levels of M30 and M65
after APAP-treatment (Figure 5B). We further assessed sera
concentrations of M30 and M65 in ALF patients. Levels of
M30 and M65 were signiﬁcantly elevated in ALF patients
(Figure 5C) and strongly correlated with release of sCD86
(M30: r ¼ 0.492, P ¼ .01; M65: r ¼ 0.420, P ¼ .03).
Having demonstrated in vitro that APAP-treated hepato-
cytes represented the main source of sB7, we postulated that
sB7 are released as early mediators from damaged hepato-
cytes and they play a key role in initiating and maintaining
elevated CTLA4 expression levels on circulating CD4þ T cells.
We examined this in vivo using a time-course APAP-inducedsion. (A) CTLA4 levels in puriﬁed CD4þ T conditioned in media
ed using ﬂow cytometry after 24-hour and 48-hour culture. (B)
ented with sera from ACLF (n¼ 15), CLD (n¼ 6) or sepsis (n¼
nce of ALF and normal sera. (C) Detection of levels of soluble
LF (n¼ 20) and HC (n¼ 10) by enzyme-linked immunosorbent
s 1 (n¼ 12), 3 (n¼ 6), 7 (n¼ 7), and 14 (n¼ 5) after admission. (E)
5), ACLF (n ¼ 20), CLD (n ¼ 15), and sepsis (n ¼ 20) patients
ted with anti-CD80 or CD86 to block soluble CD80 or CD86,
riments. Representative histograms gated on CD3þ T cells
uccinimidyl esterlabeled CD4þ T cells preconditioned in ALF
) of pretreatment with anti-CD80 or CD86 blocking antibodies.
m 5 independent experiments.
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Figure 6. PE results in the removal of circulating soluble CD80 and sCD86 and the reduction of CTLA4 levels on CD4þ T cells.
(A) Levels of soluble CD86 (left panel) and sCD80 (middle panel) were assessed by enzyme-linked immunosorbent assays
(ELISA) in sera from pre- and post-PE patients and (B) in natural course samples. (A) Right: CTLA4 levels were assessed by
ﬂow cytometry after cultures of puriﬁed CD4þ T cells from HCs in media supplemented with sera from pre- and post-PE
patients (n ¼ 7) and (B) Right: sera from natural course patients group who did not undergo PE (n ¼ 7).
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with the in vitro ﬁndings, APAP injury resulted in the release
of increased concentrations of sB7, which were detected in
the sera as early as 8 hours post APAP treatment (initiation=
Figure 5. Human and murine sources of soluble sCD80 and sC
necrosis. Apoptotic cells are stained bright green and necrotic b
ability to secrete sCD86 hepatocytes after APAP treatment. Sup
assessed by enzyme-linked immunosorbent assays (ELISA) for
markers (M30 and M65) (bottom panel). (C) Circulating levels of
(n ¼ 20), CLD (n ¼ 15), and sepsis (n ¼ 20) patients determine
sections of liver tissue from murine model of APAP-induced liv
covery from APAP-induced liver injury. Liver injury initiation (char
(24 hours), and resolution (within 5 days). (E) Left: Levels of sCD8
hours, 48 hours, and 5 days post APAP-induced liver injury a
levels (n ¼ 5 per group).phase) (P¼ .007), remained elevated between 8 and 24 hours
(peak liver injury), and signiﬁcantly decreased at 48 hours
onward (resolution phase) (P ¼ .03) to return to baseline
levels after 5 days (Figure 5E).D86. (A) Hepatocytes were ﬁrst assessed for apoptosis and
right red. (B) Primary human hepatocytes were tested for their
ernatants from 24 hours post APAP-treated hepatocytes were
concentrations of sCD86 (top panel) and for soluble cell death
M30 (left panel) and M65 (right panel) in ALF (n ¼ 25), ACLF
d in sera by ELISA. (D) Representative H&E-stained histology
er injury highlighting different stages in the evolution and re-
acterized by centrilobular hepatocyte necrosis) (8 hours), peak
6 measured in APAP-injury murine sera at 0 hours, 8 hours, 24
nd (right) corresponding alanine aminotransferase (ALT) sera
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T-LymphocyteAssociated Protein 4 Activation
Through Clearance of Circulating Soluble B7
Molecules in Acute Liver Failure
PE has been previously reported to be an important
therapeutic intervention capable of modulating innate im-
mune responses in ALF, but its effects on adaptive immunity
are not known.12 We assessed the levels of sCD80 and
sCD86 and showed that these were signiﬁcantly reduced
after PE (Figure 6A). In contrast, no reductions in sB7 levels
were detected in ALF patients who did not undergo PE
(Figure 6B). To assess whether these reductions in circu-
lating titers of sB7 molecules attenuate CTLA4 expression,
we performed in vitro cultures quantifying the CTLA4
expression on CD4þ T cells after incubation of HC-derived
CD4þ T cells in sera obtained from ALF patients before
(pre-PE) and after (post-PE) PE. Exposure of CD4þ T cell to
pre-PE sera resulted in a signiﬁcant increase in CTLA4
levels, whereas exposure to post-PE sera did not
(Figure 6A). These results indicate that PE sera drive a
markedly different phenotype of the CD4þ T-cell population
characterized by reduced levels of CTLA4.
Discussion
This study identiﬁes adaptive immune dysfunction,
mediated through CTLA4 that is triggered by soluble co-
stimulatory sB7 molecules released from the acutely
inﬂamed liver in patients with ALF. Here, we identify not
only a numerical reduction in circulating lymphocytes, but
also an increased proportion of CD4þ T cells bearing the
inhibitory, CTLA4-positive phenotype speciﬁcally in AALF
and non-AALF patients and not in other acute and chronic
hepatic inﬂammatory diseases. CTLA4 expression was
particularly elevated in memory CD4þ T cell, an immune cell
subset responsible for protective immunity against micro-
bial pathogens.34 These ﬁndings are likely to be of
pathogenic signiﬁcance in ALF, given that higher level of
CTLA4-expressing cells on admission are detected in pa-
tients who proceed to develop culture-positive secondary
infections. Therefore, the elevated CTLA4 levels in the
memory CD4þ T-cell compartment is likely to reﬂect an
impaired capacity to protect against re-infection and a
defect in producing robust effector function responses upon
microbial challenge. The increased proportion of CTLA4-
bearing cells in ALF indicates a central role for CTLA4
pathway in the predisposition to infection and that blockade
of this immunosuppressive pathway may be beneﬁcial in
restoring antimicrobial responses. We reveal that blocking
activation of the CTLA4 pathway signiﬁcantly restores
antigen-speciﬁc responses, particularly in the memory CD4þ
T-cell subset; with similar ﬁndings reported in CTLA4-
expressing memory CD8þ T cells.35 It is interesting to
note that infected ALF patients had persistent elevated
CTLA4 expression on CD4þ T cells. In this regard, several
experimental and clinical studies showed the involvement of
CTLA4-mediated negative regulation in infections.36,37
CTLA4 was reported to be expressed at higher levels in
patients with sepsis than in critically ill nonsepsis patientsand was associated with impairment in T-cell re-
sponses.38,39 Furthermore, in severe sepsis, T-cell apoptosis
and dysfunction were associated with an up-regulation of
CTLA4 on CD4þ T cells.40,41 Similarly, increased levels of
CTLA4 were implicated in viral infection-associated com-
plications.42,43 Accordingly, in murine models of bacterial
and fungal sepsis, blocking CTLA4 improved pathogen
clearance and survival.16,17
The immune regulatory functions of the B7/CD28/
CTLA4 pathway are well recognized in acquired immuno-
deﬁciency and autoimmune disorders.44,45 It is known that
membrane-bound CD80 and CD86 represent the shared li-
gands for CD28 and CTLA4.46 However, it has also been
shown that soluble forms of B7 molecules represent an
alternative powerful mechanism by which antigen-
presenting cells could modulate the signals normally
generated via membrane-bound forms of B7. Experimental
studies indicate that recombinant sB7 molecules represent a
putative mechanism for modulating T-cell responses
through either inhibition or enhancement of immune re-
sponses.47,48 In this study, we provide a novel mechanistic
explanation as to the pathogenesis of adaptive immune
dysfunction in patients with ALF. Here, we report a marked
and persistent elevation in circulating titers of sB7 mole-
cules, in particular sCD86, which strongly correlate with
indices of severity of acute hepatic injury and more speciﬁc
markers of hepatocellular death (M30/M65). In view of
these ﬁndings, we hypothesized that the origin and release
of these molecules was from the acutely injured liver. We
screened for sB7 release in parenchymal and non-
parenchymal cells and we identify that the likely origin of
sB7 molecules is from hepatocytes that have undergone
necrotic cell death after APAP administration. This ﬁnding is
corroborated by in vivo data from the murine model of
APAP-induced liver injury, where highest circulating titers
of sB7 are detected at peak hepatoxicity. Taken together, we
highlight a novel role for sB7 molecules, released after he-
patocyte cell death, that negatively regulate the adaptive
immune responses through activation of the CTLA4
pathway. Although our data support that epithelial cell
death is responsible for increased levels of sB7, in particular
sCD86, it cannot be excluded that during ALF, renal
replacement therapy alone would be a sufﬁcient modality in
clearing the sudden increase in concentrations of these
circulating proteins from the circulation. This is supported
by our ﬁndings in which we report that PE does result in
signiﬁcant reductions in concentrations of sCD86 levels in
patients with acute liver injury. Additional studies are
required to determine whether this mechanism of adaptive
immune dysfunction is common to other hepatic and non-
hepatic systemic inﬂammatory pathologies characterized by
sudden and overwhelming acute tissue injury.9
This work has identiﬁed a novel therapeutic target to
reverse immune dysfunction in patients with ALF. CTLA4
inhibitory strategies are established immune checkpoint
inhibitors in malignant and nonmalignant inﬂammatory
pathologies.16,25,49 However, there would be concern about
the use of this immunotherapeutic strategy in ALF (eg, ipi-
luminab), given its signiﬁcant side-effect proﬁle (eg, colitis,
July 2017 CTLA4 Is a Negative Regulator in ALF 275dermatitis, and autoimmune hepatitis24) and potential risk
in impairing hepatic regenerative responses.
PE has recently been shown to be of beneﬁt in patients
with ALF through clearance of damage-associated molecu-
lar patterns and other intracellular products released from
the injured liver.12 Given the fact that sB7 molecules,
released from necrotic hepatocytes, are responsible for
activation of the CTLA4 pathway, we postulated that PE
would attenuate CTLA4 levels through removal of sB7
molecules. Here we demonstrate that PE signiﬁcantly re-
duces circulating titers of sB7 molecules, in particular
sCD86, and CTLA4 expression. These data indicate that PE
has beneﬁcial effects in modulating not only innate, but
also adaptive immune responses and might therefore
represent a plausible therapeutic strategy to restore
adaptive immune responses and reverse immune paresis,
while the injured liver undergoes regeneration in ALF.
Future prospective studies are required to address this
important issue.
In summary, we show that activation of the CTLA4
pathway is responsible for adaptive immune dysfunction,
immune paresis, and infection susceptibility in patients with
ALF. Furthermore, we highlight the role of sB7 molecules,
released from acutely injured liver, in up-regulating this
suppressive pathway in circulating CD4þ T cells. PE might
represent a credible immunotherapeutic strategy aimed at
restoring adaptive immune responses against microbial
pathogens by reducing concentrations sB7 molecules and
CTLA4-bearing T cells.IC
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Supplementary Materials and Methods
Collection of Peripheral Blood Mononuclear
Cells, Isolation of CD4þ T Cells, and Generation
of Monocyte-Derived Dendritic Cells
Peripheral blood mononuclear cells were isolated from
whole blood through Ficoll-paque Plus (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) gradient centrifugation ac-
cording to the manufacturer’s instructions. CD4þT cells and
CD14þ monocytes were isolated by negative and positive
magnetic bead selection, respectively (Miltenyi Biotec,
Surrey, UK) according to the manufacturer’s instructions.
Puriﬁed cells were routinely tested for purity using ﬂow
cytometry and were >98%. Monocyte-derived DCs were
generated from isolated CD14þ cells as described previ-
ously.26 Brieﬂy, DCs were generated after 7 days of culture
in the presence of recombinant human IL4 and granulocyte-
macrophage colony-stimulating factor (eBioscience). DCs
were characterized by the expression of CD1a, CD11c, HLA-
DR, CD80, CD83, CD86, and CD14. On day 6, DCs were
matured by addition of lipopolysaccharide from Escherichia
coli (1 mg/mL) (Source BioScience, Nottingham, UK). DCs
were cultured in RPMI medium supplemented with 10%
fetal calf serum and 2 mmol L-glutamine (Invitrogen,
Paisley, UK). Viable cell counts were determined by trypan
blue exclusion.
Phenotyping Using Flow Cytometry
Peripheral blood mononuclear cells were surface
stained for markers using the following pre-titrated ﬂuo-
rochrome-labeled mouse anti-human monoclonal
antibodies: CD3-eFluor 450, CD4-Brilliant Violet 510,
CD45RA-Brilliant Violet 605, PD-1-Brilliant Violet 786,
CD45RO-ﬂuorescein isothiocyanate, CTLA4/C-C chemokine
receptor type 7phycoerythrin (PE), CD25 BD HorizonTM
PE-CF594, CD62L peridinin chlorophylleFluor710 (All
from eBioscience) and CD28/CD127 PEcyanine 7, CD8/
CD40L allophycocyanin (Becton Dickinson Ltd). Fluores-
cence minus one controls for each marker were used to set
the gates to deﬁne the different subpopulations of lym-
phocytes. Cell Viability Dye eFluor780 was used for the
exclusion of dead cells. Peripheral blood mononuclear cells
were incubated in the presence of the antibodies or the
corresponding ﬂuorescence minus one controls in the dark
for 20 minutes (except for C-C chemokine receptor type 7,
which was incubated for 45 minutes) at 4C. Single-color
controls for compensation were performed using Ultra-
Comp eBeads (eBioscience). The single stain compensation
control for the cell viability dye eFluor780 was performed
using ArC beads (ThermoFisher Scientiﬁc) following the
manufacture’s protocol. Twelve-color ﬂow cytometric ana-
lyses were performed using Fortessa ﬂow cytometer. Data
were acquired using BD FACSDiva software (Becton Dick-
inson Ltd). A total of 10,00020,000 gated events were
analyzed for each cell population. Data were analyzed using
FlowLogic software (Inivai Technologies Pty Ltd). When
assessed for T-cell proliferation using CPD dye eFluor670
labeling, cells were labeled with CD3-eFluor450,
CD4-Brilliant Violet 510, CD8 allophycocyanin, CD45RA-
Brilliant Violet 605 and CD45RO-ﬂuorescein isothiocya-
nate antibodies to assess proliferation of CD4þ T cells
memory vs naïve populations.
Primary Human Hepatocytes and Kupffer Cells
Cryopreserved hepatocytes were obtained from Life
Technologies Ltd (Paisley, UK) and cultured following
manufacturer’s instructions. Hepatocytes were ﬁrst
thawed using Cryopreserved Hepatocyte Recovery Me-
dium, cell count and viability were determined using try-
pan blue staining. Viability was >97%. Cells were then
plated using Cryopreserved Hepatocyte Plating Medium in
6 chamber slides collagen coated plates (Life Technologies
Ltd, Paisley, UK) at a lot-speciﬁc predetermined seeding
density (0.9  106 cells/mL) for 4 hours to allow adher-
ence of the cells before washing and replacing the Cry-
opreserved Hepatocyte Plating Medium with Williams’ E
supplemented medium (Life Technologies Ltd). Hepato-
cytes were allowed to further adhere overnight. Cultures
were then checked for their cell morphology and mono-
layer integrity under the microscope before being washed.
Freshly supplemented media was replaced with medium
only or medium containing 20 mM APAP (Sigma) for 24-
hour exposure. Non-APAP controls were included. Cells
were stained using apoptotic/necrotic cell kit (PromoCell
GmbH) Annexin V, Ethidium homodimer III, respectively,
and according to the manufacturer’s instructions. Cells
were then ﬁxed in 4% paraformaldehyde and mounted
using PromoFluor antifade Reagent (PromoCell GmbH).
Wide-ﬁeld epiﬂuorescence microscopy was performed on
a Leica DMI6000B equipped with a Hamamatsu ORCA-ER
CCD camera operated by the MetaMorph software (Mo-
lecular Devices, Sunnyvale, CA). Cryopreserved KCs were
obtained from Invitrogen and were recovered in Dulbec-
co’s modiﬁed Eagle medium thawing and plating media
(Life Technologies). KCs were seeded at a minimum den-
sity of 0.20.4  106 cells/mL on 24-well CellBIND plates
(VWR, Lutterworth, UK). After 3 hours of culture, the KCs
were washed and media refreshed. After overnight stim-
ulation, media was replaced with Dulbecco’s modiﬁed
Eagle medium maintenance media (Life Technologies Ltd).
KCs were then stimulated in the presence of lipopolysac-
charide (1 mg/mL) for 2 hours, washed, then co-cultured
with APAP-treated hepatocytes at a 1:4 cell ratio over-
night. Supernatants from hepatocyte and KC cultures were
collected for assessment of soluble B7 using enzyme-
linked immunosorbent assay.
Isolation and Culture of Human Biliary
Epithelial Cells
Human biliary epithelial cells (BECs) were isolated from
150 g human diseased liver tissue derived from ALF (n ¼ 3)
and CLD (n ¼ 6) patients. The liver tissue was enzymatically
digested with collagenase type 1A (Sigma), ﬁltered and
puriﬁed further via density gradient centrifugation over
Percoll (Amersham Biosciences, Little Chalfont, UK). BECs
were then extracted from the mixed nonparenchymal
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population via magnetic selection, as described previously27
and were cultured for 1 week (37C with 5% CO2) in rat-tail
collagen-coated ﬂasks. After the ﬁrst passage, BECs were
cultured for 24 hours and BEC culture supernatants were
collected to soluble B7 using ELISA.
Hepatic Endothelial Sinusoidal Cells Exposure to
Plasma from ALF Patients
Forty-eight-well cell culture plate (Costar; Corning Inc)
were precoated with type 1 rat-tail collagen (Sigma-
Aldrich). HSECs from an explanted liver with liver cirrhosis
were cultured until conﬂuent. The cells were subsequently
detached using cell-dissociating reagent TrypLE Express
Enzyme (Gibco, Life Technologies) for 5 minutes at 37C,
deactivated by addition of phosphate-buffered saline. A cell
pellet was obtained by centrifugation at 2000 rpm for 5
minutes. To each well was added 2  104 HSECs in a vol-
ume of 500 mL media (human endothelial serum free media,
10% human AB serum, recombinant vascular endothelial
growth factor, and hepatocyte growth factor (PeproTech EC
Ltd, London, UK) both at concentrations of 10 ng/mL). After
24-hour incubation, cells were washed and cultured in
serum free media supplemented with 2% fetal bovine
serum and recombinant vascular endothelial growth factor
and hepatocyte growth factor at 10 ng/mL (eBioscience).
After 24-hour culture, cells were washed and further incu-
bated for 24 hours in the presence of sera from patients
with ALF (n ¼ 6) or healthy controls (n ¼ 6) at 25%. Cells
were further activated using 10 ng/mL recombinant human
tumor necrosis factora (PeproTech) and 10 ng/mL IFN
gamma (PeproTech). Supernatants were then collected and
analyzed for sB7 molecules.
Enzyme-Linked Immunosorbent Assay and
Meso Scale Discovery Multiplex Cytokine
Detection System
Soluble CD80 and CD86 were assessed in cell culture
supernatants and human sera of HC (n ¼ 10), ALF (n ¼ 25),
ACLF (n ¼ 20), CLD (n ¼ 15), and sepsis (n ¼ 20) and
sequential samples (D1, n¼ 12; D3, n¼ 6; D7, n¼ 7; D14, n¼
5) using ELISA (eBioscience and Cusabio, College Park, MD,
respectively). In addition, levels of sCD86 were quantiﬁed in
sera from APAP-induced liver injury model murine models
using ELISA (Cusabio). Quantikine ELISA was used for IL-2
detection (R&D Systems, UK). The Human TH1/TH2 10-
Plex panel (Meso Scale Discovery [MSD]) was used to
assess the following cytokines: IFN gamma, IL1b, IL2, IL4,
IL8, IL10, IL12p70, IL13, and tumor necrosis factora. ELISA
microplates were read using the SoftMax Pro software (Mo-
lecular Devices). MSD plates were acquired on the Sector
Imager 2400 apparatus. All ELISA and MSD experiments
were performed in duplicate and according to the manufac-
turer’s instruction. Total and caspase-cleaved cytokeratin 18
(M65 and M30, respectively) were measured in sera on
admission in ALF (n¼ 25), ACLF (n¼ 20), CLD (n¼ 15), and
nonhepatic sepsis (n¼ 20) using ELISA (Peviva AB, Bromma
Sweden), and according to manufacturer’s instructions.
Levels were assessed in supernatants from APAP untreated
and treated primary human hepatocytes.
Murine Sera Samples
All research using live animals was approved by local
ethics committees (Imperial College Central Animal Welfare
Ethical Review Board) and was carried out under Home
Ofﬁce supervision in accordance with the Animal (Scientiﬁc
Procedures) Act 1986 (UK). Procedures were performed
under the authority of UK project licence 70/7578. All ef-
forts were taken to minimize animal suffering. Mice were
housed in speciﬁc pathogen free conditions in individually
ventilated cages (Techniplast UK Ltd, Kettering, UK). The
environment was controlled with a 12-hour light/dark cy-
cle, ambient temperature of 21C (±2C) and humidity of
55% (±10%). Mice had access to irradiated diet (Special
Diet Services UK, Essex, UK) and water (25 ppm chlorine)
ad libitum except when food was withdrawn for deﬁned
experimental purposes. Mice were fasted overnight for 12
hours before intraperitoneal dosing with 325 mg/kg APAP
dissolved in saline by warming to 50C for 45 minutes. One
experimental group were culled at baseline, following the
overnight fast alone. Other groups of were culled at 8 hours,
24 hours, 48 hours, and 5 days after dosing with APAP. At
necropsy the liver was excised; half was place in formalin
for ﬁxation and half was snap frozen in liquid nitrogen.
Formalin-ﬁxed liver tissue was parafﬁn-embedded,
sectioned at 10 mm thickness, and mounted onto glass
slides. Sections were stained with H&E.
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Supplementary Figure 1.Gating strategy to deﬁne lymphocyte subsets. (A) Representative dot plots of the gating strategy.
Lymphocytes were ﬁrst gated according to the forward and side scatter proﬁle. Doublets were excluded from the analyses
using side scatter area vs width discrimination. Dead cells, which were determined by positive staining for the cell viability dye,
were then excluded. (B) CD3 then CD4 and CD8 markers were used to determine the lymphocyte primary populations, which
were then gated into subsets according to the corresponding ﬂuorescence-minus-one (FMO) control (middle and bottom
panels). FCS-A, forward scatter area; SSC, side scatter.
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Supplementary Figure 2. Peripheral blood mononuclear cells (PBMCs) were analyzed for surface expression of
co-stimulatory (CD28, C62L) and inhibitory molecules (PD1, CD25 and CD40L) in CD3þCD8CD4þ T cells by ﬂow cytometry
(HC, n ¼ 20; ALF, n ¼ 45; CLD; n ¼ 15, ACLF, n ¼ 20; nonhepatic septic shock [sepsis], n ¼ 20).
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Supplementary Figure 3. Distribution of CTLA4þCD4þ in ACLF. (A) Longitudinal distribution of CTLA4 expression in
sequential samples on days 1 (n ¼ 5), 3 (n ¼ 5), 7 (n ¼ 4), and 14 (n ¼ 5) after admission. (B) CTLA4 expression in culture-
negative noninfected (n ¼ 12) and culture-positiveinfected ACLF (n ¼ 6) patients determined by ﬂow cytometry.
Supplementary Figure 4. Distribution of CTLA4 surface expression in the CD127lowCD25high T regulatory cells. (A) On day 1 of
admission (n ¼ 15) and (B) in longitudinal samples on days 1 (n ¼ 6), 3 (n ¼ 7), 7 (n ¼ 8), and 14 (n ¼ 5) after admission.
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Supplementary Figure 5. Distribution of CTLA4 surface expression in memory and naïve CD4þ T-cell subsets in sequential
samples of ALF patients who (A) developed infections and (B) the ones who did not develop infections. Left panels: Distribution
of CTLA4 expression in memory CD4þ T-cell subset. Right panels: Distribution of CTLA4 expression in the naïve CD4þ T-cell
subset.
Supplementary Figure 6. IFN-gamma levels assessed by
MSD. (A) Supernatants from cultures in the presence or
absence of a-CTLA4 blocking antibody. (B) IFN-gamma
levels in cultures preconditioned in sera treated with
a-CD80 and CD86 (right panel) (n ¼ 8).
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Supplementary Table 1.Demographic and Clinical Parameters of Acute Liver Failure, Chronic Liver Disease, Acute-on-Chronic Liver Failure, and Nonhepatic Septic
(Sepsis) Patients and Healthy Controls
Parameter HC ALF CLD ACLF Septic
Patients, n 20 45 15 20 20
Age, y 33.00 (27.2536.75) 35.00a,b,c,d (26.5048.5) 59.00 (44.561.60) 51.70 (39.0061.50) 48.00 (32.2561.25)
Etiology, n NA Acetaminophen, 35
Autoimmune, 2
Seronegative, 3
Drug-induced liver injury, 5
Alcoholic liver disease, 13
HCV, 1
Wilson’s disease, 1
Alcohol-related disease, 16e
NAFLD, 3e
Cryptogenic cirrhosis, 1e
Pneumococcal, 7
Urologic, 2
Streptococcal cellulitis,
3 Streptococcal meningitis, 1
Liver abscess, 1
Fournier’s, 1
Chest sepsis, 5
WBC, 109/L NA 6.040a,b (9.8808.130) 6.110 (4.0005.200) 8.100 (4.30013.55) 9.335 (5.52813.52)
Monocytes, 109/L NA 0.2800a,b,c (0.13000.5100) 0.6000 (0.30000.4200) 0.5750 (0.45001.050) 0.3350 (0.13000.6850)
Lymphocytes, 109/L NA 0.6800a,b,c (0.33001.190) 1.400 (0.7001.770) 0.6700 (0.45251.350) 0.6400 (0.2750.9300)
SIRS score NA 3.000*,c (2.0004.000) ND 1.500 (1.0002.000) 4.000 (3.005.000)
MELD score NA 38.00*,a,b (31.0040.00) 11.00 (9.00016.00) 22.50 (17.8026.25) NA
Child-Pugh NA NA 8.000 (6.0009.000) 10.00 (9.00013.00) NA
SOFA score (CLIFSOFA
score in ACLF)
NA 13.50a,d (7.75017.00) NA 10.00 (8.00017.00) 6.000 (4.0009.000)
Bilirubin, mmol/L NA 94.00a,b,c,d (57.00161.0) 28.00 (20.0069.00) 218.0 (110.0425.8) 14.50 (11.2525.00)
INR NA 3.840a,b,c,d (2.4506.295) 1.300 (1.2001.440) 1.655 (1.4751.950) 1.430 (1.1901.918)
Creatinine, mmol/L NA 154.0a,b,c (67.00288.0) 64.00 (61.0075.00) 79.00 (59.00116.0) 101.0 (75.00116.0)
CVVH, % (n) NA 60 (27) NA 45 (9) 40 (8)
Urea, mmol/L NA 7.200a,b (5.30013.10) 4.300 (3.1005.350) 5.500 (4.0507.325) 5.850 (3.6008.100)
AST, IU/mL NA 3584a,b,c,d (10106073) 47.00 (39.00245.0) 92.00 (58.00128.0) 49.50 (34.00241.0)
Ammonia, mmol/L NA 94.00 (65.00127.0) 89.00 (88.0090.00) ND ND
Outcomes,f % (n) NA Spontaneous survivors 69 (31)
OLT 24.4 (11)
Nonsurvivors 6.6 (3)
Survivors 100 (15) Spontaneous survivors 60 (12)
OLT 15 (3)
Nonsurvivors 25 (5)
Survivors 95 (19) Nonsurvivors 5 (1)
NOTE. Values are medians (IQR), unless otherwise noted.
AST, aspartate aminotransferase; CLIFSOFA, chronic liver failuresequential organ failure assessment; CVVH, continuous veno-venous hemoﬁltration; HCV, hepatitis C
virus; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; NA, not applicable; NAFLD, non-alcoholic fatty liver disease; ND, not determined; OLT,
orthotopic liver transplantation; SIRS score, systemic inﬂammatory response syndrome criteria score.
aP < .05.
bSigniﬁcant differences comparing ALF to CLD patients.
cSigniﬁcant differences comparing ALF to ACLF.
dSigniﬁcant differences comparing ALF to sepsis patients.
eCause for decompensation in ACLF: alcoholic hepatitis (n ¼ 11), variceal bleed (n ¼ 2), sepsis (n ¼ 7).
fOutcomes at 28 days post admission.
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Supplementary Table 2.Demographic and Clinical
Parameters of Pre-PE and Post-PE
Acute Liver Patients
Parameter Pre-PE Post-PE
Patients, n 7
Age, y 46 (36.552)
Etiology, n
APAP 5
Acute Wilson’s
disease
1
Liver trauma 1
WBC, 109/L 11.4 (8.312.8) 7.2 (5.99.4)
Monocytes,
109/L
0.1800 (0.11000.3300) 0.2400 (0.15000.3000)
Lymphocytes,
109/L
0.8 (0.30.8) 0.4 (0.30.6)
SIRS score 2 (23) 2 (23)
MELD score 40 (3940) 37 (3438)
Bilirubin, mmol/L 87 (73.597.5) 95 (88112)
INR 3.14 (3.019.12) 2.03 (1.642.32)
Creatinine, mmol/L 148 (120301) 125 (94.5-171)
Urea, mmol/L 7.600 (4.8009.400) 4.300 (2.5006.400)
AST, IU/mL 5420 (34248834) 2196 (12143587)
Ammonia, mmol/L 58.00 (39.5071.50) 45.00 (14.00201.0)
Outcome
Nonsurvivors 2
OLT 2
Survivors 3
NOTE. Values represent medians (IQR), unless otherwise
noted.
AST, aspartate aminotransferase; INR, international normal-
ised ratio; OLT, orthotopic liver transplantation; MELD, Model
for End-Stage Liver Disease; SIRS score, systemic inﬂam-
matory response syndrome criteria score; WBC, white blood
cells.
276.e8 Khamri et al Gastroenterology Vol. 153, No. 1
